These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 15098798)

  • 41. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
    Bhana N; Ormrod D; Perry CM; Figgitt DP
    Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
    Fletcher CV; Kawle SP; Kakuda TN; Anderson PL; Weller D; Bushman LR; Brundage RC; Remmel RP
    AIDS; 2000 Sep; 14(14):2137-44. PubMed ID: 11061655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Kalemeera F; D'Avolio A; Mauro S; Di Perri G; Ryan M; Mayanja-Kizza H; Khoo S; Back D; Boffito M; Merry C
    J Antimicrob Chemother; 2008 Nov; 62(5):1113-7. PubMed ID: 18641036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    Byakika-Tusiime J; Chinn LW; Oyugi JH; Obua C; Bangsberg DR; Kroetz DL
    PLoS One; 2008; 3(12):e3981. PubMed ID: 19096711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
    Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
    N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
    Katzenstein DA; Hughes M; Albrecht M; Hammer S; Para M; Murphy R; Valdez H; Haubrich R; Liou S
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1031-7. PubMed ID: 10933617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
    JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
    Burger D; Ewings F; Kabamba D; L'homme R; Mulenga V; Kankasa C; Thomason M; Gibb DM; Chintu C; Walker AS
    Ther Drug Monit; 2010 Jun; 32(3):369-72. PubMed ID: 20386361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protease inhibitor therapy in children with perinatally acquired HIV infection.
    Rutstein RM; Feingold A; Meislich D; Word B; Rudy B
    AIDS; 1997 Oct; 11(12):F107-11. PubMed ID: 9342062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
    Violari A; Lindsey JC; Hughes MD; Mujuru HA; Barlow-Mosha L; Kamthunzi P; Chi BH; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P
    N Engl J Med; 2012 Jun; 366(25):2380-9. PubMed ID: 22716976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    Chokephaibulkit K; Plipat N; Cressey TR; Frederix K; Phongsamart W; Capparelli E; Kolladarungkri T; Vanprapar N
    AIDS; 2005 Sep; 19(14):1495-9. PubMed ID: 16135903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Jonas L; Meibohm A; Holder D; Schleif WA; Condra JH; Emini EA; Isaacs R; Chodakewitz JA; Richman DD
    JAMA; 1998 Jul; 280(1):35-41. PubMed ID: 9660361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
    Hicks C; King MS; Gulick RM; White AC; Eron JJ; Kessler HA; Benson C; King KR; Murphy RL; Brun SC
    AIDS; 2004 Mar; 18(5):775-9. PubMed ID: 15075512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.